Biotricity Launches Direct-to-Patient Cardiac Screening Service
$BTCY
Medical/Dental Instruments
Health Care
Biotricity Launches Direct-to-Patient Cardiac Screening Service
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/7/2022 | $5.00 | Buy | Lake Street |
| 11/23/2021 | $6.00 | Buy | HC Wainwright & Co. |
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)
SC 13G - BIOTRICITY INC. (0001630113) (Subject)
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202
H.C. Wainwright downgraded Biotricity from Buy to Neutral
Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00
HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00
10-Q/A - BIOTRICITY INC. (0001630113) (Filer)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
NT 10-Q - BIOTRICITY INC. (0001630113) (Filer)
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202